During a live event, Mar discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell carcinoma based on recent trials.

With the end of the pandemic, sales of Pfizer’s PFE COVID products, Comirnaty and Paxlovid, have declined from their peak. However, Pfizer’s non-COVID operational revenues are improving, driven by its ...

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

The team, led by Dr Phillip Jenkins, a postdoctoral fellow in clinical informatics at Oregon Health & Science University, ...

In the EV-303/KEYNOTE-905 study, the combination of nectin-4-directed antibody-drug conjugate (ADC) Padcev (enfortumab ...

The recent data readout from studies on zanzalintinib has been positive. In June 2025, EXEL announced positive top-line results from the late-stage STELLAR-303 study. This phase III study is a global, ...